Table 1.
Baseline characteristics at time of diagnosis of unresectable or metastatic small cell prostate carcinoma (u/mSCPC)
| n=41 | Value, n (%) |
|---|---|
| Age (median, interquartile range) | 68 (62–72) |
| ECOG | |
| 0 | 6 (18.8) |
| 1 | 11 (34.4) |
| 2 | 9 (28.1) |
| 3 | 6 (18.8) |
| Unknown | 9 (28.1) |
| Stage of disease | |
| Prostate-confined | 3 (7.3) |
| Locally advanced | 11 (26.8) |
| Metastatic | 27 (65.9) |
| Diagnosis of pure small cell carcinoma | 25 (61) |
| Diagnosis by pathology | 37 (90.2) |
| Burden of disease at time of u/mSCPC diagnosis | |
| Bone | 19 (46.3) |
| Visceral | 12 (29.3) |
| Liver | 7 (17.1) |
| Lymph nodes | 20 (48.8) |
| Lung | 5 (12.2) |
| Labs at time of u/mSCPC diagnosis | |
| PSA (median, interquartile range), ug/L | 2.3 (0.27,11.7) |
| Hb (median, interquartile range), g/L | 121 (112.5, 132) |
| LDH (median, interquartile range), U/L | 323.5 (206, 562.5) |
| Albumin (median, interquartile range), g/L | 37 (32, 40) |
| ALP (median, interquartile range), U/L | 87.5 (71, 285) |
| Median Gleason score where applicable (i.e., of adenocarcinomatous portion of disease) | 9 (6,10) |
| De novo vs. transformation | |
| De novo diagnosis of SCPC | 20 (48.7%) |
| Transformation from adenocarcinoma to SCPC | 21 (51.2%) |
| Recurrence after treatment of prostate-confined disease | 4 (9.8%) |
| mCSPC | 5 (12.1%) |
| nmCRPC | 3 (7.3%) |
| mCRPC | 9 (22.0%) |
ALP: alkaline phosphatase; ECOG: Eastern Cooperative Oncology Group; Hb: hemoglobin; LDH: lactate dehydrogenase; mCSPC: metastatic castrate-sensitive prostate cancer; mCRPC: metastatic castrate-resistant prostate cancer; nmCRPC: nonmetastatic castrate-resistant prostate cancer; PSA: prostate-specific antigen.